[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614546":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":48,"collaborators":11,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Blokhin's Russian Cancer Research Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with unresectable or metastatic HER2+ BC who have received one or more cycles T-DXd","EXPERIMENTAL",null,[13],"Drug: T-DXd 5.4 mg\u002Fkg, IVD, 1 cycle every 21 days.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","T-DXd 5.4 mg\u002Fkg, IVD, 1 cycle every 21 days.","T-DXd 5.4 mg\u002Fkg, IVD, 1 cycle every 21 days. Intravenous infusion",[9],[21],{"name":22,"affiliation":23,"role":24},"Elena Artamonova","The Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":29},"CONTACT","+7 (499) 444-24-24","tatiana.titovadoc@gmail.com",[31],{"facility":32,"status":33,"city":34,"state":11,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Federal State Budgetary Institution \"N.N. Blokhin National Medical Research Center of Oncology\" оf the Ministry of Health of the Russian Federation","RECRUITING","Moscow","115522","Russia","RU",{"type":39,"coordinates":40},"Point",[41,42],37.61781,55.75204,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":47,"phoneExt":11,"email":29},"Elena А Artamonova","4994442424",{"type":49,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100614546","a-study-to-assess-the-efficiency-of-trastuzumab-deruxtecan-in-russian-breast-cancer-patients-100614546",false,"NCT07281001","A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients","Traderrus","Inclusion Criteria:\n\n1. Patients aged over 18 years old.\n2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.\n3. Patients has received Trastuzumab Deruxtecan\n4. Available medical history.\n\nExclusion Criteria:\n\n1. Incomplete medical history.\n2. Pregnancy or breast-breeding","ALL","18 Years","80 Years",{"count":61,"type":62},60,"ESTIMATED","INTERVENTIONAL",[65],"NA","This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation",[68,69],"HER2-positive Breast Cancer","Trastuzumab Deruxtecan",[69,68],"2025-12-11",{"date":73,"type":74},"2025-12-15","ACTUAL",{"date":76,"type":62},"2025-12",{"date":78,"type":62},"2026-05",{"name":5,"class":6},1]